Pacific Biosciences Completes $20.5 Million Debt Financing
Tuesday, February 5, 2013
“We are pleased that Deerfield, one of our largest shareholders, appreciates the potential in our business and is continuing to support us through this funding commitment,” stated
Under the terms of the agreement, Pacific Biosciences issued senior secured promissory notes in the aggregate principal amount of
“As long-term equity holders, we continue to believe that Pacific Biosciences’ SMRT Sequencing technology brings unique value to biological research,” commented
This announcement is neither an offer to sell nor a solicitation to buy any of the foregoing securities, nor shall there be any offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The securities have not been registered under the Securities Act of 1933, as amended (Securities Act) or any state securities laws, and may not be offered or sold in
For more information, please visit www.pacb.com.
About Pacific Biosciences
Deerfield is a leading investment management firm, committed to advancing healthcare through investment, information and philanthropy.
For more information, please visit www.deerfield.com
This press release contains forward-looking statements relating to Pacific Biosciences’ business, including its future prospects, expected use of the proceeds of the debt financing, ability to drive adoption of its Single Molecule, Real-Time (SMRT®) Sequencing technology and products, and the value and impact its products may have on biological research and human health. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Pacific Biosciences’ control and that could cause actual outcomes to differ materially from those in the forward-looking statements. Factors that could materially affect actual outcomes can be found in Pacific Biosciences’ filings with the
Quarterly Report on Form 10-Q, including those listed under the caption “Risk Factors.” Pacific Biosciences expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
CONTACT: Pacific Biosciences:
Trevin RardPacific Biosciences 650.521.8450 firstname.lastname@example.org
News Provided by Acquire Media